Cytek Biosciences, Inc. (CTKB) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Cytek Biosciences is a cell analysis solutions company leveraging Full Spectrum Profiling (FSP) technology. The company operates as a single reportable segment, manufacturing instruments (Cytek Aurora, Northern Lights, Aurora CS) and providing reagents and services globally. The company completed the acquisition of Luminex's flow cytometry and imaging business (FCI Acquisition) in February 2023.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $51,500 | $48,000 | $142,977 | $134,782 |
| Gross Profit | $29,005 | $27,178 | $77,454 | $76,378 |
| Gross Margin | 56% | 57% | 54% | 57% |
| Net Income (Loss) | $941 | $(6,456) | $(15,663) | $(17,651) |
| EPS (Diluted) | $0.01 | $(0.05) | $(0.12) | $(0.13) |
| Cash & Equivalents | $162,272 | $167,299 | As of Sept 30, 2024 | |
| Marketable Securities | $115,505 | $95,111 | As of Sept 30, 2024 | |
| Long-Term Debt | $1,236 | $1,648 | As of Sept 30, 2024 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 7% year-over-year (YoY) in Q3 and 6% for the nine-month period. Service revenue grew significantly (25% in Q3, 41% for 9M) due to an expanding installed base, while product revenue was flat to slightly down (3% up in Q3, 2% down for 9M).
- Profitability: The company reported a net income of $0.9 million in Q3 2024, a significant improvement from a net loss of $6.5 million in Q3 2023. This was driven by a reduced operating loss, foreign exchange gains, and a tax benefit.
- Operating Expenses: Research and Development (R&D) expenses decreased 12% in Q3 and 11% for the 9M period, primarily due to headcount reductions. Sales and Marketing expenses remained relatively flat.
- Share Repurchases: The company repurchased 2.2 million shares in Q3 2024 for approximately $11.9 million under a $50 million program approved in June 2024. As of period end, $35.4 million remained available under this program.
- Inventory Reduction: Inventory levels decreased by $14.1 million from year-end 2023 to $46.8 million, contributing to positive operating cash flow.
Guidance, Outlook, and Risks
- Outlook: Management expects expenses to remain relatively flat while continuing to invest in R&D and commercial infrastructure. The company anticipates recurring service revenue will become an increasingly important contributor as the installed base expands.
- Legal Proceedings: On August 14, 2024, Beckman Coulter, Inc. sued Cytek alleging patent infringement regarding flow cytometers. Cytek has denied liability and filed a counterclaim for false patent marking. The outcome is uncertain.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2024, due to material weaknesses in the control environment and control activities (specifically regarding accounting resources and IT general controls). A remediation plan is underway.
- Market Risks: Risks include reliance on single-source suppliers for key components, potential trade tensions between the U.S. and China, and the impact of macroeconomic conditions on biotech/pharma customer spending.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of the remediation plan for the material weaknesses in internal controls over financial reporting.
- Beckman Coulter Litigation: Monitor the status of the patent infringement lawsuit and potential financial exposure or operational restrictions.
- Service Revenue Sustainability: Assess the durability of the high growth in service revenue as a driver for future margins.
- Share Repurchase Program: Track the utilization of the remaining $35.4 million repurchase authorization and its impact on liquidity.
- Inventory Management: Confirm that inventory write-downs remain controlled following the recent reduction in inventory levels.